Recursion reaches FDA alignment on Phase 3 trial design for REC-4881 in FAP
RXRX•Recursion said it secured FDA alignment on a registrational Phase 3 trial design for REC-4881, with enrollment of approximately 200 adults scheduled to begin in the second half of 2027.
1. Planned Phase 3 trial
The trial will enroll approximately 200 adults with familial adenomatous polyposis following colectomy or proctocolectomy. Its primary endpoint will count removal of adenomas measuring at least 10 mm anywhere in the gastrointestinal tract as an event.
2. Earlier study results
Previously reported Phase 2 TUPELO results showed substantial, rapid reductions in polyp burden, including larger, higher-risk polyps. The article states that FAP has no approved pharmacologic therapies.




